Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (19322)	4/18/1998 4:51:00 PM
From: Henry Niman	Respond to of 32384

W, The annual report uses "stage".

To: WTDEC who wrote (19322)	4/18/1998 10:21:00 PM
From: Henry Niman	Read Replies (4) \| Respond to of 32384

I have linked Ligand's Pipeline Timeline to the front page at home.att.net The colors actually vary by browser, but it's pretty easy to see what happened in each year and also easy to see where current efforts are (and future efforts will be) concentrated. The anti-androgen LGD1331 is most interesting. In one section of the table, its development has moved into IND territory suggesting that an announcement will be made soon. The BPH part remained just shy of IND filing, but prostate cancer and hirsutism have "crossed the line". Based on earlier comments by David Molowa (when he initiated coverage), I would expect an IND by LGND for prostate cancer, and an announcement of a new partner for the hirsutism applications.